Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in July 2018 on request of the Sponsor.
On 1 October 2010, orphan designation (EU/3/10/796) was granted by the European Commission to XOMA Ireland Ltd, Ireland, for recombinant humanised anti-human interleukin-1 beta monoclonal antibody for the treatment of Behçet's disease.
The sponsorship was transferred to Les Laboratoires Servier, France, in December 2011 and subsequently to XOMA UK Limited, United Kingdom, in February 2016.
Recombinant humanised anti-human interleukin-1 beta monoclonal antibody
|Disease / condition||
Treatment of Behçet's Disease
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
c/o Arnold & Porter (UK) LLP
25 Old Broad Street
London EC2N 1HQ
Tel. +44 (0)20 7786 6104
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.